Nanobiotix (EURONEXT:NANO), (NASDAQ:NBTX) is a company dedicated to revolutionizing cancer treatment through its pioneering work in nanomedicine. Its primary focus lies in developing and commercializing novel therapeutics based on the innovative use of nanoparticles to directly target and destroy cancerous cells, while minimizing damage to healthy tissue. Nanobiotix’s flagship project, NBTXR3, is a first-in-class radioenhancer designed to increase the efficacy of radiotherapy, a cornerstone treatment for cancer. The company's objectives are centered on advancing the clinical development of its product pipeline, securing regulatory approvals, and establishing partnerships to ensure global access to its technologies.